NYAB: Valuation problematic despite growth outlook
NYAB’s Q2 report was unsurprising in terms of main operational lines and guidance, due to the preliminary information provided in connection with the profit warning. Our estimate changes remained limited in light of the report that was pretty much in line with our expectations. We expect that NYAB will continue to grow quite rapidly in the next few years and profitability will gradually improve with worst cost pressures easing. However, this has already been priced into the share more than our forecasts, and at the current share price, the risk/return ratio has, in our opinion, turned very weak. Thus, we reiterate our EUR 0.55 target price but lower our recommendation to Sell (was Reduce).
